Heron Therapeutics Inc [HRTX] stock prices are up 1.82% to $2.80 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The HRTX shares have gain 9.80% over the last week, with a monthly amount glided 7.69%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 28, March 2024, Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference. In a post published today on Yahoo Finance, Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that Craig Collard, Chief Executive Officer of Heron, will participate in a fireside chat on Wednesday, April 10, 2024, at 11:00 AM ET at the 23rd Annual Needham Virtual Healthcare Conference. The conference is being held in a virtual format, April 8-11, 2024.
From an analyst’s perspective:
Heron Therapeutics Inc [NASDAQ: HRTX] stock has seen the most recent analyst activity on March 13, 2024, when Needham reiterated its Buy rating and also boosted its price target to $5 from $4. Previously, Guggenheim started tracking the stock with Buy rating on May 27, 2020, and set its price target to $24. On February 20, 2020, Needham reiterated its Buy rating and revised its price target to $48 on the stock. Needham reiterated its Buy rating and decreased its price target to $64 on January 16, 2019. Evercore ISI initiated its recommendation with a Outperform and recommended $56 as its price target on April 05, 2018. Mizuho reiterated a Buy rating for this stock on March 19, 2018, and upped its price target to $35. In a note dated March 01, 2018, Needham reiterated an Buy rating on this stock and boosted its target price from $28 to $30.
The stock price of Heron Therapeutics Inc [HRTX] has been fluctuating between $0.50 and $3.22 over the past year. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. Heron Therapeutics Inc [NASDAQ: HRTX] shares were valued at $2.80 at the most recent close of the market. An investor can expect a potential return of 78.57% based on the average HRTX price forecast.
Analyzing the HRTX fundamentals
The Heron Therapeutics Inc [NASDAQ:HRTX] reported sales of 127.04M for trailing twelve months, representing a surge of 14.00%. Gross Profit Margin for this corporation currently stands at 0.49% with Operating Profit Margin at -0.87%, Pretax Profit Margin comes in at -0.87%, and Net Profit Margin reading is -0.87%. To continue investigating profitability, this company’s Return on Assets is posted at -0.5, Equity is 3.92 and Total Capital is -0.77. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -5.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.73 points at the first support level, and at 2.66 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.85, and for the 2nd resistance point, it is at 2.90.
Heron Therapeutics Inc [HRTX] reported earnings per share of -$0.07 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.16/share, meaning a difference of $0.09 and a surprise factor of 56.20%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.17 per share as compared to estimates of -$0.29 per share, a difference of $0.12 representing a surprise of 41.40%.
Ratios To Look Out For
It’s worth pointing out that Heron Therapeutics Inc [NASDAQ:HRTX]’s Current Ratio is 2.37. In addition, the Quick Ratio stands at 1.84 and the Cash Ratio stands at 0.36. Considering the valuation of this stock, the price to sales ratio is 3.31.
Transactions by insiders
Recent insider trading involved Forbes William P, EVP, Chief Development Officer, that happened on Nov 17 ’23 when 25000.0 shares were purchased. Chief Executive Officer, Collard Craig A completed a deal on Nov 16 ’23 to buy 0.15 million shares. Meanwhile, EVP, Chief Financial Officer Duarte Ira bought 85000.0 shares on Nov 16 ’23.
